From the Journals

Intermittent fasting can lead to type 2 diabetes remission


 

72 patients with diabetes for an average of 6.6 years

“Despite a widespread public consensus that [type 2 diabetes] is irreversible and requires drug treatment escalation, there is some evidence of the possibility of remission,” Dr. Yang and colleagues write in their article.

They aimed to evaluate the effectiveness of intermittent fasting for diabetes remission and the durability of diabetes remission at 1 year.

Diabetes remission was defined having a stable A1c less than 6.5% for at least 3 months after discontinuing all antidiabetic medications, confirmed in at least annual A1c measurements (according to a 2021 consensus statement initiated by the American Diabetes Association).

Between 2019 and 2020, the researchers enrolled 72 participants aged 38-72 years who had had type 2 diabetes (duration 1 to 11 years) and a body mass index (BMI) of 19.1-30.4 kg/m2. Patients were randomized 1:1 to the intermittent fasting group or control group.

Baseline characteristics were similar in both groups. Patients were a mean age of 53 years and roughly 60% were men. They had a mean BMI of 24 kg/m2, a mean duration of diabetes of 6.6 years, and a mean A1c of 7.6%, and they were taking an average of 1.8 glucose-lowering medications.

On fasting days, patients in the intervention group received a Chinese Medical Nutrition Therapy kit that provided approximately 840 kcal/day (46% carbohydrates, 46% fat, 8% protein). The kit included a breakfast of a fruit and vegetable gruel, lunch of a solid beverage plus a nutritional rice composite, and dinner of a solid beverage and a meal replacement biscuit, which participants reconstituted by mixing with boiling water. They were allowed to consume noncaloric beverages.

On nonfasting days, patients chose foods ad libitum based on the 2017 Dietary Guidelines for Diabetes in China, which recommend approximately 50%-65% of total energy intake from carbohydrates, 15%-20% from protein, and 20%-30% from fat, and had greater than or equal to 5 g fiber per serving.

Patients in the control group chose foods ad libitum from the dietary guidelines during the entire study.

The study received funding from the National Natural Science Foundation of China. The authors have reported no relevant financial disclosures.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Dapagliflozin reduces hospitalizations in patients with CKD
MDedge Endocrinology
Diabetes decision tool yields ‘modest’ benefit in low-resource clinics
MDedge Endocrinology
Guideline stresses new strategies for hypoglycemia management
MDedge Endocrinology
Cold water immersion can have benefits
MDedge Endocrinology
FDA okays Dexcom G7 continuous glucose monitoring system
MDedge Endocrinology
Given the choice, T2D patients find their own best meds
MDedge Endocrinology
Cognitive behavioral therapy app lowers A1c in type 2 diabetes
MDedge Endocrinology
Low-carb, high-fat, calorie-unrestricted diet improves type 2 diabetes
MDedge Endocrinology
ADA issues 2023 ‘Standards of Care’ for diabetes: Focus on tight BP, lipids
MDedge Endocrinology
DELIVER subanalysis ‘seals deal’ for dapagliflozin in HF
MDedge Endocrinology